Major Challenges For Neuropsychiatric Drug Market Reported By Medmeme, LLC

Share Article

Since 2010 five of the top-selling brand psychiatric drugs have lost patent protection leading analysts to predict a multi-billion-dollar drop in market value, perhaps by half.

News Image

Medmeme, LLC., as a global leader in comprehensive, integrated medical and science information database platforms, has released the new syndicated TrendsmemeTM Report: Neuroscience – Psychiatric Diseases. Its primary focus is on depression, schizophrenia, and anxiety because this is where R&D concentration is, and these indications made up a great deal of the $25 billion worldwide sales in the category in 2010. As the leading disability in the US, psychiatric disorders will affect, at sometime in their lives, 45% of the population. Drugs used in treatment have been a major contributor to the overall direct costs associated with these conditions. Guidelines specifying lower-cost generic product use of off-patent drugs could be a major game-changer in treatment, and is shaping planning strategies in companies large and small, MedMeme reports.

Eli Lilly ranks first in treatments for neuropsychiatric disorders with both a leading antidepressant (Cymbalta) and a leading antipsychotic (Zyprexa). Other very active companies are: Janssen/J&J, Pfizer, AstraZeneca, Bristol-Myers Squibb, Lundbeck, and Forest. However, aside from Eli Lilly, it is now mostly midsize and smaller pharmaceutical companies that account for the bulk of R&D activity in the psychiatric category. The mid-size and smaller firms increasingly active in pipeline R&D include: Sunovion, Vanda Pharmaceuticals, Alexia, Alkermes, Shire, Acadia Pharmaceuticals, Targacept, Allon Therapeutics, Avineuro, Intracellular Therapies, and Bionomics. A logical question might be, as in other therapeutic categories as well, what big-pharma partnering or acquisition activity to watch for on the horizon.

Medmeme CEO Mahesh Naithani looks at the challenges: “We can see some of the plans firms have, but in our database we can see even more clearly the full spectrum of what the past indicates to inform future planning. For example, the top selling drugs are from leaders who most exposed understanding of their products regarding disease indications, treatment patterns, and so forth, garnering the most attention at medical conference presentations and in journal abstracts. Companies that do this very well, starting at the top, are: Eli Lilly, Janssen/J&J, Pfizer, AstraZeneca, BMS, Lundbeck, and Forest. You do have to have the best Thought Leader physicians and experts to do this. Without their expertise, reimbursement payers and prescribing practitioners can resist using newer treatments. Then you’ll see some good new drugs relegated to second or third-line treatment. There are also other important factors that can make a difference, such as early messaging about research, broad indication coverage, merger and acquisition potential, developing drugs with new mechanisms. Our report goes into all these details. It provides the necessary strategic planning fodder to use for success.”

The syndicated TrendsmemeTM Report: Neuroscience – Psychiatric Diseases can be purchased separately, or, along with other MedMeme reports in the new series, at discounted pricing. To learn more, contact us, or see our website,

Medmeme, LLC                         
Yan Barshay, Executive Vice President         
+1 212-725-5992                        


Medmeme, LLC.
Ray Wright, Vice President, Sales
+ 1 508-278-4595

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Yan Barshay

Raymond Wright
MedMeme LLC
Email >
Visit website